Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

B Phase 1 trials for HWK-007 and HWK-016 are ongoing; an IND submission for HWK-206 is on track for mid-2026 Cash, cash equivalents and short-term…
posteditor
posteditor
Articles: 21727

Other News